SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU) - moderated -- Ignore unavailable to you. Want to Upgrade?


To: patlawche11 who wrote (45898)4/25/2018 12:58:45 PM
From: erippetoe  Read Replies (1) | Respond to of 63276
 
is the population of this group larger or smaller than TNBC?



To: patlawche11 who wrote (45898)4/25/2018 2:32:02 PM
From: patlawche113 Recommendations

Recommended By
dorightbythem
drtom1234
erippetoe

  Read Replies (1) | Respond to of 63276
 
FWIW...IMMU132 status changed today from active, recruiting to active, not recruiting for Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers. So...I would imagine they are currently not treating new/additional patients for UC, as well as for other indications in this trial.

clinicaltrials.gov